Dr Najeed Aadil· @daakhsaab · X·· 2 天前评分70
正文 · 原文
MASTERPLAN (#ESMO26 , n=74): SBRT + chemotherapy vs chemotherapy alone:
🔹 Median OS: 22 vs 14 months
🔹 Median PFS: 11.9 vs 6.3 months
🔹 12-month locoregional recurrence: 20.2% vs 52%
Promising phase II results; confirmation needed.
#ESMO26
@OncoDailyGI
@larvo
174 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
3136RO按 Rapid oral 1: Gastrointestinal tumour, upper digestive 对上
Randomised phase II study of mFOLFIRINOX ± SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial
https://esmocongress.esmo.org来源：Dr Najeed Aadil · x.com